Facioscapulohumeral muscular dystrophy

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Facioscapulohumeral muscular dystrophy
Timelapse of DUX4 being expressed in FSHD Muscle Cells[1]
SpecialtyNeurology Edit this on Wikidata

Facioscapulohumeral muscular dystrophy (FSHMD, FSHD or FSH)—originally named Landouzy-Dejerine[2]—is a usually autosomal dominant inherited form of muscular dystrophy (MD)[3] that initially affects the skeletal muscles of the face (facio), scapula (scapulo) and upper arms (humeral). FSHD is the third most common genetic disease of skeletal muscle. Orpha.net lists the prevalence as 4/100,000[4] while a 2014 population-based study in the Netherlands reported a significantly higher prevalence of 12 in 100,000.[5]

Symptoms may develop in early childhood and are usually noticeable in the teenage years, with 95% of affected individuals manifesting disease by age 20 years. A progressive skeletal muscle weakness usually develops in other areas of the body as well; often the weakness is asymmetrical. Life expectancy can rarely be threatened by respiratory insufficiency, and up to 20% of affected individuals become severely disabled, requiring use of a wheel chair or mobility scooter. Non-muscular symptoms frequently associated with FSHD include subclinical sensorineural hearing loss and retinal telangiectasia. In more than 95% of known cases, the disease is associated with contraction of the D4Z4 repeat in the 4q35 subtelomeric region of chromosome 4. Seminal research published in August 2010 now shows the disease requires a second mechanism, which for the first time provides a unifying theory for its underlying genetics. The second mechanism is a "toxic gain of function" of the DUX4 gene, which is the first time in genetic research that a "dead gene" has been found to "wake up" and cause disease.[6][7]

Building on the 2010 unified theory of FSHD, researchers in 2014 published the first proposed pathophysiology definition of the disease and four viable therapeutic targets for possible intervention points.[8]

Signs and Symptoms[edit]

Because of the extreme variability of the disease, an authoritative and scientifically confirmed set of symptoms does not yet exist. There may even be no signs which are apparent in a younger individual or in an individual with mild disease. FSHD can affect many skeletal muscles, with great variation among individuals. Muscle weakness usually becomes noticeable on one side of the body and not the other; this is a hallmark of the disease. Individual muscles can weaken while nearby muscles remain healthy.


  • Musculoskeletal pain, most often in the shoulders and lower back.
  • Facial muscle weakness (eyelid drooping, inability to whistle, difficulty pronouncing the letters M, B, and P, or facial expressions that appear diminished, depressed, angry, or fatigued)
  • Shoulder girdle weakness (difficulty working with the arms raised, sloping shoulder, winged scapula). Scapula can be positioned laterally, superiorly, and downwardly rotated, appearing as if the scapula is herniating up and over the rib cage. Muscles attached to the superior scapula are more visible anteriorly.
  • Asymmetrical weakening of the biceps
  • Asymmetrical loss of pectoral muscle, often with prominent anterior axillary folds crowded on top of the pectorals laterally
  • Loss of strength in abdominal muscles (manifesting as a positive Beevor's sign, a protuberant abdomen, and/or lumbar lordosis)
  • Foot drop due to affected tibialis anterior (shin muscle)
  • Mild retinal blood vessel abnormalities, such as telangiectasias or microaneurysms, are common, with one study placing the incidence at 50% of FSHD cases. A severe form of this mimics Coat's disease, which is found in about 1% of FSHD cases and is more frequently associated with large 4q35 deletions.[9][10]

Less Common

  • Weakness in the legs (difficulty walking, hips held in slight flexion)
  • Affected breathing is seen in one-third of wheelchair-bound patients. Use of a wheelchair and kyphoscoliosis increase the likelihood of respiratory impairment. However, need for ventilator support is rare.[9] In a Dutch study, approximately 1% of patients required (nocturnal or diurnal) ventilatory support.[11]
  • Hearing loss is no more common in typical FSHD cases compared to those without FSHD. However, in those with large 4q35 deletions, there is an increased likelihood of high-frequency hearing loss.[9]


  • Head droop (head held forward and down) due to neck weakness.


Chromosome 4.svg
An illustration by Peter Jones PhD describing the complex interplay of genetics and epigenetics in FSHD.

FSHD Type 1 (also called FSHMD1A) (4q35 deletion)[edit]

More than 95% of cases of FSHD are associated with the deletion of integral copies of a tandemly repeated 3.2kb unit (D4Z4 repeat) at the subtelomeric region 4q35 on Chromosome 4 of the human genome, of which a normal chromosome includes between 11-150 repetitions of D4Z4.[12] There are both heterochromatin and euchromatin structures within D4Z4 and one putative gene called DUX4.[12][13] Inheritance is autosomal dominant, though up to one-third of the cases appear to be from de novo (new) mutations. The heterochromatin is specifically lost in the deletions of FSHD while the euchromatin structures remain.[12] If the entire region is removed, there are birth defects, but no specific defects on skeletal muscle. Individuals appear to require the existence of 11 or fewer repeat units to be at risk for FSHD.

In addition, a few cases of FSHD are the result of rearrangements between subtelomeric chromosome 4q and a subtelomeric region of 10q. This location contains a tandem repeat structure highly homologous to 4q35.[14] Disease occurs when the translocation results in a critical loss of tandem repeats to the 4q site.

FSHD Type 2[edit]

A large family was reported with a phenotype indistinguishable from FSHD in which no pathological changes at the 4q site or translocation of 4q-10q are found.[15][16] It had been suggested that this may be due to limitations in the available tests.[17]

In 2012, a majority of FSHD2 cases were reported linked to mutations in the SMCHD1 gene on chromosome 18. This leads to substantially reduced levels of SMCHD1 protein, and subsequently, hypomethylation of the 4q D4Z4 region. The FSHD2 phenotype arises in individuals who inherited both the SMCHD1 mutations plus a normal sized D4Z4 region on a permissive 4qA allele. This establishes a genetic/mechanistic intersection of FSHD1 and FSHD2.[18]

A Unifying Theory[edit]

On 19 August 2010, a paper entitled A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy was published in Science showing that the candidate gene DUX4 undergoes a "toxic gain of function" as a result of single nucleotide polymorphisms in the region distal to the last D4Z4 repeat. According to the research, this leads to a "canonical polyadenylation signal for transcripts derived from DUX4".[7] This is the first time in the history of genetics in which "junk" DNA has been shown to reanimate and cause disease. The documentation of the conditions under which the DUX4 gene became reanimated answered the question of why no one whose dead gene was repeated more than 10 times ever got FSHD but only some people with fewer than 10 copies did get the disease[6] Several organizations including The New York Times highlighted this research (See MDA, FSH Society, University of Rochester, NYT).

Dr. Francis Collins, who oversaw the first sequencing of the Human Genome with the National Institutes of Health stated:[6]

“If we were thinking of a collection of the genome’s greatest hits, this would go on the list,”

Daniel Perez, co-founder, President and CEO of the FSH Society hailed the new findings saying:

"This is a long-sought explanation of the exact biological workings of a disease that affects an estimated one in 14,000 or 22,100 Americans and 490,000 worldwide,” he said, adding that this discovery “creates an enormous opportunity for research to develop ways to prevent or treat FSHD.”

The MDA stated that:

"The new findings will make it easier to diagnose FSHD in someone with symptoms and predict who will develop the disease in someone without symptoms. Now, the hunt is on for which proteins or genetic instructions (RNA) cause the problem for muscle tissue in FSHD."

Quoted in the University of Rochester press release, one of the report's co-authors, Silvère van der Maarel of the University of Leiden, stated that

“It is amazing to realize that a long and frustrating journey of almost two decades now culminates in the identification of a single small DNA variant that differs between patients and people without the disease. We finally have a target that we can go after.”

The original identification of the D4Z4 deletions was found in 1992. This research now shows that a second mechanism is needed for FSHD to be present and that the remaining versions of the DUX4 become more active (open for transcription) because the DNA at the tip of chromosome 4 is less tightly coiled as a result of the deletions.

Chronology of Important FSHD-related Genetic Research[edit]

  • Landouzy and Dejerine describe a form of childhood progressive muscle atrophy with a characteristic involvement of facial muscles and distinct from pseudohypertrophic (Duchenne’s MD) and spinal muscle atrophy in adults.[19]


  • Landouzy and Dejerine describe progressive muscular atrophy of the scapulo-humeral type.[20]


  • Tyler and Stephens study 1249 individuals from a single kindred with FSHD traced to a single ancestor and describe a typical Mendelian inheritance pattern with complete penetrance and highly variable expression. The term facioscapulohumeral dystrophy is introduced.[21]


  • Padberg provides the first linkage studies to determine the genetic locus for FSHD in his seminal thesis "Facioscapulohumeral disease."[22]



  • The genetic defect in FSHD is linked to a region (4q35) near the tip of the long arm of chromosome 4.[24]


  • FSHD, in both familial and de novo cases, is found to be linked to a recombination event that reduces the size of 4q EcoR1 fragment to < 28 kb (50–300 kb normally).[25]


  • 4q EcoR1 fragments are found to contain tandem arrangement of multiple 3.3-kb units (D4Z4), and FSHD is associated with the presence of < 11 D4Z4 units.[26]
  • A study of seven families with FSHD reveals evidence of genetic heterogeneity in FSHD.[27]


  • The heterochromatic structure of 4q35 is recognized as a factor that may affect the expression of FSHD, possibly via position-effect variegation.[28]
  • DNA sequencing within D4Z4 units shows they contain an open reading frame corresponding to two homeobox domains, but investigators conclude that D4Z4 is unlikely to code for a functional transcript.[28][29]


  • The terms FSHD1A and FSHD1B are introduced to describe 4q-linked and non-4q-linked forms of the disease.[30]


  • FSHD Region Gene1 (FRG1) is discovered 100 kb proximal to D4Z4.[31]


  • Monozygotic twins are identified with identical 23 kb EcoR1 fragments but vastly different clinical expression of FSHD.[32]


  • Complete sequencing of 4q35 D4Z4 units reveals a promoter region located 149 bp 5' from the open reading frame for the two homeobox domains, indicating a gene that encodes a protein of 391 amino acid protein (later corrected to 424 aa[33]), given the name DUX4.[34]


  • Investigators assessed the methylation state (heterochromatin is more highly methylated than euchromatin) of DNA in 4q35 D4Z4. An examination of SmaI, MluI, SacII, and EagI restriction fragments from multiple cell types, including skeletal muscle, revealed no evidence for hypomethylation in cells from FSHD1 patients relative to D4Z4 from unaffected control cells or relative to homologous D4Z4 sites on chromosome 10. However, in all instances, D4Z4 from sperm was hypomethylated relative to D4Z4 from somatic tissues.[35]


  • A polymorphic segment of 10 kb directly distal to D4Z4 is found to exist in two allelic forms, designated 4qA and 4qB. FSHD1 is associated solely with the 4qA allele.[36]
  • Three genes (FRG1, FRG2, ANT1) located in the region just centromeric to D4Z4 on chromosome 4 are found in isolated muscle cells from individuals with FSHD at levels 10 to 60 times greater than normal, showing a linkage between D4Z4 contractions and altered expression of 4q35 genes.[37]


  • A further examination of DNA methylation in different 4q35 D4Z4 restriction fragments (BsaAI and FseI) showed significant hypomethylation at both sites for individuals with FSHD1, non-FSHD-expressing gene carriers, and individuals with phenotypic FSHD relative to unaffected controls.[38]


  • Contraction of the D4Z4 region on the 4qB allele to < 38 kb does not cause FSHD.[39]


  • Transgenic mice overexpressing FRG1 are shown to develop severe myopathy.[40]


  • The DUX4 open reading frame is found to have been conserved in the genome of primates for over 100 million years, supporting the likelihood that it encodes a required protein.[41]
  • Researchers identify DUX4 mRNA in primary FSHD myoblasts and identify in D4Z4-transfected cells a DUX4 protein, the overexpression of which induces cell death.[33]
  • DUX4 mRNA and protein expression are reported to increase in myoblasts from FSHD patients, compared to unaffected controls. Stable DUX4 mRNA is transcribed only from the most distal D4Z4 unit, which uses an intron and a polyadenylation signal provided by the flanking pLAM region. DUX4 protein is identified as a transcription factor, and evidence suggests overexpression of DUX4 is linked to an increase in the target paired-like homeodomain transcription factor 1 (PITX1).[42]


  • The terms FSHD1 and FSHD2 are introduced to describe D4Z4-deletion-linked and non-D4Z4-deletion-linked genetic forms, respectively. In FSHD1, hypomethylation is restricted to the short 4q allele, whereas FSHD2 is characterized by hypomethylation of both 4q and both 10q alleles.[43]
  • Splicing and cleavage of the terminal (most telomeric) 4q D4Z4 DUX4 transcript in primary myoblasts and fibroblasts from FSHD patients is found to result in the generation of multiple RNAs, including small noncoding RNAs, antisense RNAs and capped mRNAs as new candidates for the pathophysiology of FSHD.[44]


  • A unifying genetic model of FSHD describes the requirement for FSHD-type deletions of D4Z4 to occur on a permissive allele containing a poly-A adenylation signal (PAS) in the pLAM1 region adjacent to the final D4Z4 unit. The non-permissive 4qB allele lacks a PAS, does not generate a stable DUX4 transcript, and is not linked to FSHD. The corresponding D4Z4 region on chromosome 10 (10q26) lacks a PAS altogether, and deletions in this region are not involved in FSHD.[45]
  • DUX4 is found actively transcribed in skeletal muscle biopsies and primary myoblasts. FSHD-affected cells produce a full length transcript, DUX4-fl, whereas alternative splicing in unaffected individuals results in the production of a shorter, 3'-truncated transcript (DUX4-s). The low overall expression of both transcripts in muscle is attributed to relatively high expression in a small number of nuclei (~ 1 in 1000). Higher levels of DUX4 expression in human testis (~100 fold higher than skeletal muscle) suggest a developmental role for DUX4 in human development. Higher levels of DUX4-s (vs DUX4-fl) are shown to correlate with a greater degree of DUX-4 H3K9me3-methylation.[46]


  • Some, but not all, instances of FSHD2 are linked to mutations in the SMCHD1 gene on chromosome 18. This leads to substantially reduced levels of SMCHD1 protein, and subsequently, hypomethylation of the 4q D4Z4 region. The FSHD2 phenotype arises in individuals who inherited both the SMCHD1 mutations plus a normal sized D4Z4 region on a permissive 4qA allele. This establishes a genetic/mechanistic intersection of FSHD1 and FSHD2.[18]
  • The prevalence of FSHD-like D4Z4 deletions on permissive alleles is significantly higher than the prevalence of FSHD in the general population, challenging the criteria for molecular diagnosis of FSHD.[47]
  • When expressed in primary myoblasts, DUX4-fl acted as a transcriptional activator, producing a > 3-fold change in the expression of 710 genes.[48] A subsequent study using a larger number of samples identified DUX4-fl expression in myogenic cells and muscle tissue from unaffected relatives of FSHD patients, per se, is not sufficient to cause pathology, and that additional modifiers are determinants of disease progression.[49]
  • A mechanism is proposed in which DBE-T (D4Z4 Regulatory Element transcript), a long non-coding RNA transcribed from a 4q35 region proximal to D4Z4, is expressed in FSHD, leading to the recruitment of the Trithorax group protein Ash1L, an increase in H3k36me2-methylation, and ultimately de-repression of 4q35 genes.[50]


  • Mutations in SMCHD1 are shown to act as a disease modifier, increasing the severity of FSHD1 in individuals who also exhibit a contraction of D4Z4.[51]
  • Transgenic mice carrying D4Z4 arrays from an FSHD1 allele (with 2.5 D4Z4 units), although lacking an obvious FSHD-like skeletal muscle phenotype, are found to recapitulate important genetic expression patterns and epigenetic features of FSHD.[52]


  • DUX4-fl and downstream target genes are expressed in skeletal muscle biopsies and biopsy-derived cells of fetuses with FSHD-like D4Z4 arrays, indicating that molecular markers of FSHD are already expressed during fetal development.[53]
  • In an open access article in Skeletal Muscle, researchers "review how the contributions from many labs over many years led to an understanding of a fundamentally new mechanism of human disease" and articulate how the unifying genetic model and subsequent research represent a "pivot-point in FSHD research, transitioning the field from discovery-oriented studies to translational studies aimed at developing therapies based on a sound model of disease pathophysiology." They describe the consensus mechanism of pathophysiology for FSHD as a "inefficient repeat-mediated epigenetic repression of the D4Z4 macrosatellite repeat array on chromosome 4, resulting in the variegated expression of the DUX4 retrogene, encoding a double-homeobox transcription factor, in skeletal muscle." [8]

Society and Culture[edit]

FSHD Society[edit]

In 1991 the FSHD Society (named "FSH Society" until 2019)[54] was founded by two individuals with FSHD, Daniel Perez and Stephen Jacobsen. The FSHD Society raised funding to provide seed grants for FSHD research, advocated for the field to standardize the name of the disease as "facioscapulohumeral muscular dystrophy" and "FSHD", and co-wrote the MD-CARE Act, passed into law in 2001, which for the first time mandated federal resources, including National Institutes of Health funding, for all muscular dystrophies. The FSHD Society has grown into the world's largest grassroots organization advocating for patient education and scientific and medical research.[55]

FSHD Foundation[edit]

In 2007 the FSHD Global Research Foundation was established to increase the amount of funding available to research bodies. The Foundation has identified 13 priority areas of interest for FSHD research.[56]


In 2009 the FSHD-EUROPE was founded by European associations.[57]


A schematic of D4Z4 locus on chromosome 4: The D4Z4 locus is in the sub-telomeric region of 4q. The figure shows a three repeat D4Z4 array. CEN indicates the centromeric end and TEL indicates the telomeric end. The DUX4 gene is shown as a gray rectangle with exon 1 and exon 2 in each repeat and exon 3 in the pLAM region telomeric to the last partial repeat (numbered 1, 2, and 3). PAS indicates the polyadenylation site on the permissive 4qA allele that is not present on the non-permissive 4qB allele or on chromosome 10. The arrowed lines represent: Blue, DBE-T transcripts (2.4, 4.4, and 9.8 kb) found in FSHD cells and reported to de-repress DUX4 expression; Black and red, transcripts in the sense and antisense direction were detected in both FSHD and control cells and might originate from the mapped sense promoters (black) and anti-sense promoters (red) with dashed lines indicating areas that might be degraded or produce si-like small RNAs. NDE, non-deleted element identified as the transcription start site for the DBE-T transcripts.[8]

In 2014, researchers undertook a "review [of] how the contributions from many labs over many years led to an understanding of a fundamentally new mechanism of human disease" and articulated how the unifying genetic model and subsequent research represent a "pivot-point in FSHD research, transitioning the field from discovery-oriented studies to translational studies aimed at developing therapies based on a sound model of disease pathophysiology." They proposed a consensus mechanism of pathophysiology for FSHD as a "inefficient repeat-mediated epigenetic repression of the D4Z4 macrosatellite repeat array on chromosome 4, resulting in the variegated expression of the DUX4 retrogene, encoding a double-homeobox transcription factor, in skeletal muscle." [8]

In more lay terms, the D4Z4 repeats (most people have about 200 or so) normally keep DUX4 repressed (the repeat-mediated repression). When there are drastically fewer repeats (approximately 10 or less) in addition to the small genetic change on Chromosome 4 called a haplotype polymorphism, DUX4 expresses itself (the inefficient repression component) via a complex set of mechanisms that make the genetic neighborhood around the DUX4 gene more conducive to gene expression (the epigenetic component). The figure on the right describes this process in detail.


Genetic Testing[edit]

Since the early 2000s, genetic testing has been the gold standard for FSHD diagnosis. The most common protocol uses restriction fragment length polymorphism to measure the size of the D4Z4 segment on chromosome 4q35, with subsequent haplotype testing. If the restriction fragment length is less than 38 kilobases (kb) and the 4qA haplotype is present, FSHD1 is likely. If the D4Z4 length is greater than 38 kb and the 4qA haplotype is present, methylation of 4q35 is assessed; a lack of methylation indicates that FSHD2 is likely. As of 2019, this test is considered accurate and specific.[9] It is only performed by a limited set of labs in the US, such as Athena diagnostics under test code 405. When cost is prohibitive (genetic testing is expensive) or a diagnosis of FSHD is not suspected, patients and doctors may rely on one or more of the following tests, all of which are far less accurate and specific than the genetic test:[58]

Alternative Testing[edit]

  • Creatine kinase (CK) blood level: CK is an enzyme found in muscle, and it is released into the blood when muscles become damaged. CK levels are normal to mildly elevated in FSHD.[9]
  • Electromyogram (EMG): This test measures the electrical activity in the muscle. EMG shows nonspecific signs of muscle damage or irritability.[9]
  • Nerve conduction velocity (NCV): This test measures the how fast signals travel from one part of a nerve to another. The nerve signals are measured with surface electrodes (similar to those used for an electrocardiogram) or needle electrodes.
  • Muscle biopsy: Through outpatient surgery a small piece of muscle is removed (usually from the arm or leg) and evaluated with a variety of biochemical tests. Researchers are attempting to match results of muscle biopsies with DNA tests to better understand how variations in the genome present themselves in tissue anomalies.
  • Muscle MRI: Muscle MRI is sensitive for detecting muscle damage, even in paucisymptomatic cases. Because of the particular muscle involvement patterns of FSHD, MRI can help differentiate FSHD from other muscle diseases, directing molecular diagnosis. MRI is also useful in studying the natural history of the disease. [59][60]
  • Electrical impedance myography is being studied as a way to measure muscle damage in the research setting, which would aid in pharmaceutical testing.[9]
  • Quality of life can be measured with specific questionnaires.[61]

Muscle Involvement Patterns in MRI[edit]


  • Physiotherapy could improve patients' functional status by providing therapeutic exercises.
  • Occupational therapy can sometimes be used for training in activities of daily living (ADLs) and to help cope with new devices to make things easier.
  • Aerobic exercise has been shown to reduce chronic fatigue and decelerate fatty infiltration of muscle in FSHD.[65][66] The American Academy of Neurology (ANN) recommends that people with FSHD engage in low-intensity aerobic exercise to promote energy levels, muscle health, and bone health.[9]
  • Cognitive behavioral therapy (CBT) has been shown to reduce chronic fatigue in FSHD, and it also decelerates fatty infiltration of muscle when directed towards increasing daily activity.[65][66]

Scapular Winging[edit]

  • Scapular bracing can help correct scapular positioning, improving shoulder function.
  • Scapulopexy, an orthopedic procedure, involves tethering the scapula to the ribs, vertebrae, or other scapula using tendon grafts, wire, or other means. No fusion between bones is achieved. Many different procedures exist, and outcomes are different for each. Scapulopexies are considered to be more susceptible to long-term failure than procedures involving bony fusion.
  • Scapulothoracic fusion, an orthopedic procedure to achieve bony fusion between scapula and the ribs, usually increases shoulder active range of motion, improves shoulder function, decreases pain, and improves cosmetic appearance by eliminating winging and restoring shoulder contours.[67][68] Although active range of motion is increased, passive range of motion decreases. Namely, the patient gains the ability to slowly flex and abduct their shoulders to 90+ degrees, but they lose the ability to "throw" their arm up to a full 180 degrees.[9]
  • Tendon transfer (an orthopedic surgery), including pectoralis major transfer and the Eden-Lange procedure, although potentially helpful in specific cases of FSHD, is generally not recommended.[69]

Foot Drop[edit]

  • Ankle-foot orthoses can improve walking, balance, and quality of life.[70]
  • Tendon transfer, such as the Bridle procedure, in selected cases can correct foot drop.[71][72]


  • As of 2020, no pharmaceuticals have proven effective for treating FSHD.
  • Based on the consensus model of pathophysiology, researchers propose four approaches for therapeutic intervention:[8]
    1. enhance the epigenetic repression of the D4Z4
    2. target the DUX4 mRNA, including altering splicing or polyadenylation;
    3. block the activity of the DUX4 protein
    4. inhibit the DUX4-induced process, or processes, that leads to pathology.

Current Development[edit]

  • Losmapimod, a selective inhibitor of p38α/β mitogen-activated protein kinases, was identified by Fulcrum Therapeutics as a potent suppressor of DUX4 in vitro.[73] A phase IIb clinical trial started in July 2019 and is expected to end in August 2020.[74]
  • Antisense nucleotides directed against DUX4 messenger RNA are in the preclinical stage. Antisense nucleotides have been shown to reduce DUX4 and downregulate DUX4 target genes, with few off-target effects. The current challenge is delivering the nucleotides to the muscle cells; these antisense nucleotides have poor ability to penetrate muscle.[9]
  • Gene therapy consisting of microRNAs (miRNAs) directed against DUX4, delivered by viral vectors, are in the preclinical stage. In mouse FSHD models, miRNAs have shown to reduce DUX4, protect against muscle pathology, and prevent loss of grip strength.[9]

Potential Pharmaceuticals[edit]

  • Inhibition of the hyaluronic acid (HA) pathway is a potential therapy. One study found that many DUX4-induced molecular pathologies are mediated by HA signaling, and inhibition of HA biosynthesis with 4-methylumbelliferone prevented these molecular pathologies.[75]
  • P300 inhibition has shown to inhibit the deleterious effects of DUX4[76]
  • BET inhibitors have been shown to reduce DUX4 expression.[77]
  • Casein kinase 1 (CK1) inhibitors have been identified by Facio Therapies, a Dutch pharmaceutical company, as repressors of DUX4 expression. Facio Therapies claims that CK1 inhibition leaves myotube fusion intact, unlike BET inhibitors, p38 MAPK inhibitors, and β2 agonists.[78][79]
  • Antioxidants could potentially reduce the effects of FSHD. One study found that vitamin C, vitamin E, zinc gluconate, and selenomethionine supplementation increased endurance and strength of the quadriceps, but had no significant benefit on walking performance.[80] Further study is warranted.[9]
  • ACVR2B inhibition has shown to increase muscle mass and improve muscular function in mouse models of Duchenne muscular dystrophy.[81] Nothing has been published regarding ACVR2B inhibition in the context of FSHD.

Past Development[edit]

  • Prednisone, a steroid, was trialed in FSHD on the basis of its therapeutic effect in Duchenne muscular dystrophy. It had no clinical effect in the short term. The study was unable to assess long term effects of prednisone on FSHD.[82]
  • Oral albuterol, a β2 agonist, improved muscle mass and certain measures of strength in clinical trials. However, it did not improve global strength or function.[83][84][85] Interestingly, after DUX4 was identified as an integral part of FSHD pathophysiology, drug screens showed that β2 agonists reduce DUX4 expression.[77]
  • Diltiazem, a calcium channel blocker, was trialed in FSHD on the bases of anecdotal reports of it being beneficial and the theory that calcium dysregulation may play a part in muscle cell death (this was before identification of DUX4 as part of pathophysiology). No clinical benefits were seen, and long term effects on FSHD were unable to be assessed.[86]
  • MYO-029 (Stamulumab) is an experimental myostatin-inhibiting drug developed by Wyeth Pharmaceuticals for the treatment of muscular dystrophy. Myostatin is a protein that inhibits the growth of muscle tissue. MYO-029 is a recombinant human antibody designed to bind and inhibit the activity of myostatin.[87] A 2005/2006 study was completed by Wyeth in Collegeville, PA, and included participants afflicted with FSHD. The study could not prove its efficacy and did not proceed further.[88]
  • ACE-083 is a TGF-β inhibitor developed by Acceleron Pharma. It failed to show efficacy in treating FSHD in a phase II clinical trial, though as of December 2019 it is still being developed for treatment of Charcot–Marie–Tooth disease.[89]


The prevalence is widely placed at 1/20,000, but the exact prevalence is not known. A November 2008 report from Orpha.net, an organization backed by the Institut National de la Santé et de la Recherche Médicale (INSERM), listed a prevalence of 7/100,000, but the May 2014 version of this report places the prevalence at 4/100,000.[4] A 2014 population-based study in the Netherlands reported a significantly higher prevalence of 12 in 100,000.[4]


FSHD was first described in 1884 by French physicians Louis Landouzy and Joseph Dejerine. In their paper of 1886, Landouzy and Dejerine drew attention to the familial nature of the disorder and mentioned that four generations were affected in the kindred that they had investigated.[90] Formal definition of FSHD's clinical features didn't occur until 1952 when a large Utah family with FSHD was studied. Beginning about 1980 an increasing interest in FSHD led to increased understanding of the great variability in the disease and a growing understanding of the genetic and pathophysiological complexities. By the late 1990s, researchers were finally beginning to understand the regions of Chromosome 4 associated with FSHD.[12]

Since the publication of the unifying theory in 2010, researchers continued to refine their understanding of DUX4. With increasing confidence in this work, researchers proposed the first a consensus view in 2014 of the pathophysiology of the disease and potential approaches to therapeutic intervention based on that model.[8]

A chronology of milestones in FSHD genetic research is included above in the "Genetics" section.

Over the years, FSHD has, at various times, been referred to as:

  • Landouzy-Dejerine[2]
  • Landouzy-Dejerine syndrome[90]
  • Erb-Landouzy-Dejerine syndrome[90]
  • Landouzy-Dejerine dystrophy or atrophy[90]
  • faciohumeroscapular


  1. ^ Rickard, Amanda; Petek, Lisa; Miller, Daniel (August 5, 2015). "Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways". Hum. Mol. Genet. 24 (20): 5901–14. doi:10.1093/hmg/ddv315. PMC 4581613. PMID 26246499. Retrieved September 10, 2015.
  2. ^ a b disease overview, MDA, date accessed 6 March 2007
  3. ^ Lemmers RJ, Wohlgemuth M, van der Gaag KJ, et al. (November 2007). "Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy". Am. J. Hum. Genet. 81 (5): 884–94. doi:10.1086/521986. PMC 2265642. PMID 17924332.
  4. ^ a b Prevalence of rare diseases: Bibliographic data, www.orpha.net, May 2014, Number 1, Orphanet Report Series
  5. ^ Deenen JC, Arnts H, van der Maarel SM, Padberg GW, Verschuuren JJ, Bakker E, Weinreich SS, Verbeek AL, van Engelen BG (2014). "Population-based incidence and prevalence of facioscapulohumeral dystrophy". Neurology. 83 (12): 1056–9. doi:10.1212/WNL.0000000000000797. PMC 4166358. PMID 25122204.
  6. ^ a b c Kolata, Gina (19 August 2010). "Reanimated 'Junk' DNA Is Found to Cause Disease". The New York Times. Retrieved 29 August 2010.
  7. ^ a b Lemmers RJ, van der Vliet PJ, Klooster R, Sacconi S, Camaño P, Dauwerse JG, Snider L, Straasheijm KR, van Ommen GJ, Padberg GW, Miller DG, Tapscott SJ, Tawil R, Frants RR, van der Maarel SM (19 August 2010). "A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy". Science. 329 (5999): 1650–3. Bibcode:2010Sci...329.1650L. doi:10.1126/science.1189044. PMC 4677822. PMID 20724583.
  8. ^ a b c d e f Tawil, Rabi; van der Maarel, SM; Tapscott, SJ (10 June 2014). "Facioscapulohumeral dystrophy: the path to consensus on pathophysiology". Skeletal Muscle. 4 (1): 12. doi:10.1186/2044-5040-4-12. PMC 4060068. PMID 24940479.
  9. ^ a b c d e f g h i j k l Wagner, Kathryn R. (December 2019). "Facioscapulohumeral Muscular Dystrophies". CONTINUUM: Lifelong Learning in Neurology. 25 (6): 1662–1681. doi:10.1212/CON.0000000000000801. PMID 31794465.
  10. ^ Lindner, Moritz; Holz, Frank G; Charbel Issa, Peter (2016-04-27). "Spontaneous resolution of retinal vascular abnormalities and macular oedema in facioscapulohumeral muscular dystrophy". Clinical & Experimental Ophthalmology. 44 (7): 627–628. doi:10.1111/ceo.12735. ISSN 1442-6404. PMID 26933772.
  11. ^ Wohlgemuth M, van der Kooi EL, van Kesteren RG, van der Maarel SM, Padberg GW (2004). "Ventilatory support in facioscapulohumeral muscular dystrophy". Neurology. 63 (1): 176–8. CiteSeerX doi:10.1212/01.wnl.0000133126.86377.e8. PMID 15249635.
  12. ^ a b c d Impossible Things: Through the looking glass with FSH Dystrophy Researchers, Margaret Wahl, MDA, Quest magazine, Vol 14, No 2, March–April 2007
  13. ^ Dixit M, Ansseau E, Tassin A, et al. (November 2007). "DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1". Proc. Natl. Acad. Sci. U.S.A. 104 (46): 18157–62. Bibcode:2007PNAS..10418157D. doi:10.1073/pnas.0708659104. PMC 2084313. PMID 17984056.
  14. ^ Rossi M, Ricci E, Colantoni L, et al. (2007). "The Facioscapulohumeral muscular dystrophy region on 4qter and the homologous locus on 10qter evolved independently under different evolutionary pressure". BMC Med. Genet. 8: 8. doi:10.1186/1471-2350-8-8. PMC 1821008. PMID 17335567.
  15. ^ Gilbert JR, Stajich JM, Wall S, et al. (August 1993). "Evidence for heterogeneity in facioscapulohumeral muscular dystrophy (FSHD)". Am. J. Hum. Genet. 53 (2): 401–8. PMC 1682358. PMID 8328457.
  16. ^ Speer MC, Pericak-Vance MA, Stajich JM, et al. (September 1997). "Further exclusion of FSHD1B from the telomeric region of 10q". Neurogenetics. 1 (2): 151–2. doi:10.1007/s100480050023. PMID 10732819. Archived from the original on 1999-11-22. Retrieved 2009-02-19.
  17. ^ Deak KL, Lemmers RJ, Stajich JM, et al. (February 2007). "Genotype-phenotype study in an FSHD family with a proximal deletion encompassing p13E-11 and D4Z4". Neurology. 68 (8): 578–82. doi:10.1212/01.wnl.0000254991.21818.f3. PMID 17229919.
  18. ^ a b Lemmers, RJ; Tawil, R; Petek, LM; et al. (Dec 2012). "Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2". Nature Genetics. 44 (12): 1370–1374. doi:10.1038/ng.2454. PMC 3671095. PMID 23143600.
  19. ^ Landouzy; Dejerine (1884). "De la myopathie atrophique progressive (myopathie héréditaire, débutant dans l'enfance par la face, sans altération du système nerveux)". Comptes Rendus de l'Académie des Sciences. 98: 53–55.
  20. ^ Landouzy; Dejerine (1886). "Contribution à l'étude de la myopathie atrophique progressive (myopathie atrophique progressive, à type scapulo-huméral)". Comptes Rendus des Séances de la Société de Biologie. 38: 478–481.
  21. ^ Tyler, Frank; Stephens, FE (April 1950). "Studies in disorders of muscle. II Clinical manifestations and inheritance of facioscapulohumeral dystrophy in a large family". Annals of Internal Medicine. 32 (4): 640–660. doi:10.7326/0003-4819-32-4-640. PMID 15411118.
  22. ^ Padberg, GW (1982-10-13). Facioscapulohumeral disease (Thesis). Leiden University.
  23. ^ Koenig, M; Hoffman, EP; Bertelson, CJ; Monaco, AP; Feener, C; Kunkel, LM (Jul 31, 1987). "Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals". Cell. 50 (3): 509–517. doi:10.1016/0092-8674(87)90504-6. PMID 3607877.
  24. ^ Wijmenga, C; Padberg, GW; Moerer, P; et al. (April 1991). "Mapping of facioscapulohumeral muscular dystrophy gene to chromosome 4q35-qter by multipoint linkage analysis and in situ hybridization". Genomics. 9 (4): 570–575. doi:10.1016/0888-7543(91)90348-I. PMID 2037288.
  25. ^ Wijmenga, C; Hewitt, JE; Sandkuijl, LA; et al. (Sep 1992). "Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy". Nature Genetics. 2 (1): 26–30. doi:10.1038/ng0992-26. PMID 1363881.
  26. ^ van Deutekom, JC; Wijmenga, C; van Tienhoven, EA; et al. (Dec 1993). "FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit". Human Molecular Genetics. 2 (12): 2037–2042. doi:10.1093/hmg/2.12.2037. PMID 8111371.
  27. ^ Gilbert, JR; Stajich, JM; Wall, S; et al. (Aug 1993). "Evidence for heterogeneity in facioscapulohumeral muscular dystrophy (FSHD)". American Journal of Human Genetics. 53 (2): 401–408. PMC 1682358. PMID 8328457.
  28. ^ a b Winokur, ST; Bengtsson, U; Feddersen, J; et al. (May 1994). "The DNA rearrangement associated with facioscapulohumeral muscular dystrophy involves a heterochromatin-associated repetitive element: implications for a role of chromatin structure in the pathogenesis of the disease". Chromosome Research. 2 (3): 225–234. doi:10.1007/bf01553323. PMID 8069466.
  29. ^ Hewitt, JE; Lyle, R; Clark, LN; et al. (Aug 1994). "Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy". Human Molecular Genetics. 3 (8): 1287–1295. doi:10.1093/hmg/3.8.1287. PMID 7987304.
  30. ^ Gilbert, JR; Speer, MC; Stajich, J; et al. (Oct 1995). "Exclusion mapping of chromosomal regions which cross hybridise to FSHD1A associated markers in FSHD1B". Journal of Medical Genetics. 32 (10): 770–773. doi:10.1136/jmg.32.10.770. PMC 1051697. PMID 8558552.
  31. ^ van Deutekom, JC; Lemmers, RJ; Grewal, PK; et al. (May 1996). "Identification of the first gene (FRG1) from the FSHD region on human chromosome 4q35". Human Molecular Genetics. 5 (5): 581–590. doi:10.1093/hmg/5.5.581. PMID 8733123.
  32. ^ Tupler, R; Barbierato, L; et al. (Sep 1998). "Identical de novo mutation at the D4F104S1 locus in monozygotic male twins affected by facioscapulohumeral muscular dystrophy (FSHD) with different clinical expression". Journal of Medical Genetics. 35 (9): 778–783. doi:10.1136/jmg.35.9.778. PMC 1051435. PMID 9733041.
  33. ^ a b Kowaljow, V; Marcowycz, A; Ansseau, E; et al. (Aug 2007). "The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein". Neuromuscular Disorders. 17 (8): 611–623. doi:10.1016/j.nmd.2007.04.002. PMID 17588759.
  34. ^ Gabriels, J; Beckers, MC; Ding, H; et al. (Aug 5, 1999). "Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element". Gene. 236 (1): 25–32. doi:10.1016/S0378-1119(99)00267-X. PMID 10433963.
  35. ^ Tsien, F; Sun, B; Hopkins, NE; et al. (Nov 2001). "Methylation of the FSHD syndrome-linked subtelomeric repeat in normal and FSHD cell cultures and tissues". Molecular Genetics and Metabolism. 74 (3): 322–331. doi:10.1006/mgme.2001.3219. PMID 11708861.
  36. ^ Lemmers, RJ; de Kievit, P; Sandkuijl, L; et al. (Oct 2002). "Facioscapulohumeral muscular dystrophy is uniquely associated with one of the two variants of the 4q subtelomere". Nature Genetics. 32 (2): 235–236. doi:10.1038/ng999. PMID 12355084.
  37. ^ Gabellini, D; Green, MR; Tupler, R (Aug 9, 2002). "Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle". Cell. 110 (3): 339–348. doi:10.1016/S0092-8674(02)00826-7. PMID 12176321.
  38. ^ van Overveld, PG; Lemmers, RJ; Sandkuijl, LA; et al. (Dec 2003). "Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy". Nature Genetics. 35 (4): 315–317. doi:10.1038/ng1262. PMID 14634647.
  39. ^ Lemmers, RJ; Wohlgemuth, M; Frants, RR; Padberg, GW; Morava, E; van der Maarel, SM (Dec 2004). "Contractions of D4Z4 on 4qB subtelomeres do not cause facioscapulohumeral muscular dystrophy". The American Journal of Human Genetics. 75 (6): 1124–1130. doi:10.1086/426035. PMC 1182148. PMID 15467981.
  40. ^ Gabellini, D; D'Antona, G; Moggio, M; et al. (Feb 23, 2006). "Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1". Nature. 439 (7079): 973–977. Bibcode:2006Natur.439..973G. doi:10.1038/nature04422. PMID 16341202.
  41. ^ Clapp, J; Mitchell, LM; Bolland, DJ; et al. (Aug 2007). "Evolutionary conservation of a coding function for D4Z4, the tandem DNA repeat mutated in facioscapulohumeral muscular dystrophy". The American Journal of Human Genetics. 81 (2): 264–279. doi:10.1086/519311. PMC 1950813. PMID 17668377.
  42. ^ Dixit, M; Ansseau, E; Tassin, A; et al. (Nov 13, 2007). "DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1". Proceedings of the National Academy of Sciences of the USA. 104 (46): 18157–18162. Bibcode:2007PNAS..10418157D. doi:10.1073/pnas.0708659104. PMC 2084313. PMID 17984056.
  43. ^ de Greef, JC; Lemmers, RJ; van Engelen, BG; et al. (Oct 2009). "Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD". Human Mutation. 30 (10): 1449–1459. CiteSeerX doi:10.1002/humu.21091. PMID 19728363.
  44. ^ Snider, L; Asawachaicharn, A; Tyler, AE; et al. (Jul 1, 2009). "RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy". Human Molecular Genetics. 18 (13): 2414–2430. doi:10.1093/hmg/ddp180. PMC 2694690. PMID 19359275.
  45. ^ Lemmers, RJ; van der Vliet, PJ; Klooster, R; et al. (Sep 24, 2010). "A unifying genetic model for facioscapulohumeral muscular dystrophy" (PDF). Science. 329 (5999): 1650–1653. Bibcode:2010Sci...329.1650L. doi:10.1126/science.1189044. PMC 4677822. PMID 20724583. Archived from the original (PDF) on 2014-06-05.
  46. ^ Snider, L; Geng, LN; Lemmers, RJ; et al. (Oct 2010). "Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene". PLoS Genetics. 6 (10): e1001181. doi:10.1371/journal.pgen.1001181. PMC 2965761. PMID 21060811.
  47. ^ Scionti, I; Greco, F; Ricci, G; et al. (Apr 6, 2012). "Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy". The American Journal of Human Genetics. 90 (4): 628–635. doi:10.1016/j.ajhg.2012.02.019. PMC 3322229. PMID 22482803.
  48. ^ Geng, LN; Yao, Z; Snider, L; et al. (Jan 17, 2012). "DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy". Developmental Cell. 22 (1): 38–51. doi:10.1016/j.devcel.2011.11.013. PMC 3264808. PMID 22209328.
  49. ^ Jones, TI; Chen, JC; Rahimov, F; et al. (Oct 15, 2012). "Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis". Human Molecular Genetics. 21 (20): 4419–4430. doi:10.1093/hmg/dds284. PMC 3459465. PMID 22798623.
  50. ^ Cabianca, DS; Casa, Casa; Bodega, B; et al. (May 11, 2012). "A long ncRNA links copy number variation to a polycomb/trithorax epigenetic switch in FSHD muscular dystrophy". Cell. 149 (4): 819–831. doi:10.1016/j.cell.2012.03.035. PMC 3350859. PMID 22541069.
  51. ^ Sacconi, S; Lemmers, RJ; Balog, J; et al. (Oct 3, 2013). "The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1". The American Journal of Human Genetics. 93 (4): 744–751. doi:10.1016/j.ajhg.2013.08.004. PMC 3791262. PMID 24075187.
  52. ^ Krom, YD; Thijssen, PE; Young, JM; et al. (Apr 2013). "Intrinsic Epigenetic Regulation of the D4Z4 Macrosatellite Repeat in a Transgenic Mouse Model for FSHD". PLoS Genetics. 9 (4): e1003415. doi:10.1371/journal.pgen.1003415. PMC 3616921. PMID 23593020.
  53. ^ Ferreboeuf, M; Mariot, V; Bessieres, B; et al. (Jan 1, 2014). "DUX4 and DUX4 downstream target genes are expressed in fetal FSHD muscles". Human Molecular Genetics. 23 (1): 171–181. doi:10.1093/hmg/ddt409. PMID 23966205.
  54. ^ Kinoshita, June. "What's in a name? – FSHD Society". FSHD Society. Retrieved 18 August 2019.
  55. ^ "FSH Society".
  56. ^ "FSHD".
  57. ^ "FSHD Europe : 光の中のたこ焼きを食べたいと思って30年 – なんのこっちゃ!".
  58. ^ FSHD Fact Sheet Archived 2006-03-06 at the Wayback Machine, MDA, 11/1/2001
  59. ^ a b c Tasca, G; Monforte, M; Iannaccone, E; Laschena, F; Ottaviani, P; Leoncini, E; Boccia, S; Galluzzi, G; Pelliccioni, M; Masciullo, M; Frusciante, R; Mercuri, E; Ricci, E (2014). "Upper girdle imaging in facioscapulohumeral muscular dystrophy". PLOS ONE. 9 (6): e100292. Bibcode:2014PLoSO...9j0292T. doi:10.1371/journal.pone.0100292. PMC 4059711. PMID 24932477.
  60. ^ a b c Gerevini, S; Scarlato, M; Maggi, L; Cava, M; Caliendo, G; Pasanisi, B; Falini, A; Previtali, SC; Morandi, L (March 2016). "Muscle MRI findings in facioscapulohumeral muscular dystrophy". European Radiology. 26 (3): 693–705. doi:10.1007/s00330-015-3890-1. PMID 26115655.
  61. ^ Dany, Antoine; Barbe, Coralie; Rapin, Amandine; Réveillère, Christian; Hardouin, Jean-Benoit; Morrone, Isabella; Wolak-Thierry, Aurore; Dramé, Moustapha; Calmus, Arnaud; Sacconi, Sabrina; Bassez, Guillaume; Tiffreau, Vincent; Richard, Isabelle; Gallais, Benjamin; Prigent, Hélène; Taiar, Redha; Jolly, Damien; Novella, Jean-Luc; Boyer, François Constant (2015). "Construction of a Quality of Life Questionnaire for slowly progressive neuromuscular disease". Quality of Life Research. 24 (11): 2615–2623. doi:10.1007/s11136-015-1013-8. ISSN 0962-9343. PMID 26141500.
  62. ^ Rijken, NH; van der Kooi, EL; Hendriks, JC; van Asseldonk, RJ; Padberg, GW; Geurts, AC; van Engelen, BG (December 2014). "Skeletal muscle imaging in facioscapulohumeral muscular dystrophy, pattern and asymmetry of individual muscle involvement". Neuromuscular Disorders. 24 (12): 1087–96. doi:10.1016/j.nmd.2014.05.012. PMID 25176503.
  63. ^ Mair, D; Huegens-Penzel, M; Kress, W; Roth, C; Ferbert, A (2017). "Leg Muscle Involvement in Facioscapulohumeral Muscular Dystrophy: Comparison between Facioscapulohumeral Muscular Dystrophy Types 1 and 2". European Neurology. 77 (1–2): 32–39. doi:10.1159/000452763. PMID 27855411.
  64. ^ Olsen, DB; Gideon, P; Jeppesen, TD; Vissing, J (November 2006). "Leg muscle involvement in facioscapulohumeral muscular dystrophy assessed by MRI". Journal of Neurology. 253 (11): 1437–41. doi:10.1007/s00415-006-0230-z. PMID 16773269.
  65. ^ a b Voet, N; Bleijenberg, G; Hendriks, J; de Groot, I; Padberg, G; van Engelen, B; Geurts, A (18 November 2014). "Both aerobic exercise and cognitive-behavioral therapy reduce chronic fatigue in FSHD: an RCT". Neurology. 83 (21): 1914–22. doi:10.1212/WNL.0000000000001008. PMID 25339206.
  66. ^ a b Janssen, B; Voet, N; Geurts, A; van Engelen, B; Heerschap, A (3 May 2016). "Quantitative MRI reveals decelerated fatty infiltration in muscles of active FSHD patients". Neurology. 86 (18): 1700–7. doi:10.1212/WNL.0000000000002640. PMID 27037227.
  67. ^ Demirhan, Mehmet; Uysal, Ozgur; Atalar, Ata Can; Kilicoglu, Onder; Serdaroglu, Piraye (31 March 2009). "Scapulothoracic Arthrodesis in Facioscapulohumeral Dystrophy with Multifilament Cable". Clinical Orthopaedics and Related Research. 467 (8): 2090–2097. doi:10.1007/s11999-009-0815-9. PMC 2706357. PMID 19333668.
  68. ^ DeFranco, Michael J.; Nho, Shane; Romeo, Anthony A. (April 2010). "Scapulothoracic Fusion". Journal of the American Academy of Orthopaedic Surgeons. 18 (4): 236–42. doi:10.5435/00124635-201004000-00006. PMID 20357232.
  69. ^ Abrams, Jeffrey S.; Bell, Robert H.; Tokish, John M. ADVANCED RECONSTRUCTION OF SHOULDER. AMER ACAD OF ORTHOPAEDIC. ISBN 9781975123475.
  70. ^ Aprile, I; Bordieri, C; Gilardi, A; Lainieri Milazzo, M; Russo, G; De Santis, F; Frusciante, R; Iannaccone, E; Erra, C; Ricci, E; Padua, L (April 2013). "Balance and walking involvement in facioscapulohumeral dystrophy: a pilot study on the effects of custom lower limb orthoses". European Journal of Physical and Rehabilitation Medicine. 49 (2): 169–78. PMID 23138679.
  71. ^ Krishnamurthy, S; Ibrahim, M (January 2019). "Tendon Transfers in Foot Drop". Indian Journal of Plastic Surgery. 52 (1): 100–108. doi:10.1055/s-0039-1688105. PMC 6664842. PMID 31456618.
  72. ^ Chiodo, Chris; Bluman, Eric M. (2011-10-21). Tendon transfers in the foot and ankle. Saunders. p. 421. ISBN 9781455709243. Retrieved 1 January 2020.
  73. ^ "Fulcrum Therapeutics Acquires Global Rights to Losmapimod, a Potential Disease-Modifying Therapy for Facioscapulohumeral Muscular Dystrophy". BioSpace. Retrieved 12 August 2019.
  74. ^ "Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)". ClinicalTrials.gov. United States National Library of Medicine. Retrieved 12 August 2019.
  75. ^ DeSimone, Alec M.; Leszyk, John; Wagner, Kathryn; Emerson, Charles P. (11 December 2019). "Identification of the hyaluronic acid pathway as a therapeutic target for facioscapulohumeral muscular dystrophy". Science Advances. 5 (12): eaaw7099. doi:10.1126/sciadv.aaw7099. PMC 6905861. PMID 31844661.
  76. ^ Bosnakovski, D; da Silva, MT; Sunny, ST; Ener, ET; Toso, EA; Yuan, C; Cui, Z; Walters, MA; Jadhav, A; Kyba, M (September 2019). "A novel P300 inhibitor reverses DUX4-mediated global histone H3 hyperacetylation, target gene expression, and cell death". Science Advances. 5 (9): eaaw7781. doi:10.1126/sciadv.aaw7781. PMC 6739093. PMID 31535023.
  77. ^ a b Campbell, AE; Oliva, J; Yates, MP; Zhong, JW; Shadle, SC; Snider, L; Singh, N; Tai, S; Hiramuki, Y; Tawil, R; van der Maarel, SM; Tapscott, SJ; Sverdrup, FM (4 September 2017). "BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells". Skeletal Muscle. 7 (1): 16. doi:10.1186/s13395-017-0134-x. PMC 5584331. PMID 28870238.
  78. ^ "Facio to present at the World Muscle Society Congress". Facio Therapies. 30 September 2019. Retrieved 9 November 2019.
  79. ^ "Facio reveals novel mechanism targeting the cause of FSHD". Facio Therapies. 24 June 2019. Retrieved 9 November 2019.
  80. ^ Passerieux, E; Hayot, M; Jaussent, A; Carnac, G; Gouzi, F; Pillard, F; Picot, MC; Böcker, K; Hugon, G; Pincemail, J; Defraigne, JO; Verrips, T; Mercier, J; Laoudj-Chenivesse, D (April 2015). "Effects of vitamin C, vitamin E, zinc gluconate, and selenomethionine supplementation on muscle function and oxidative stress biomarkers in patients with facioscapulohumeral dystrophy: a double-blind randomized controlled clinical trial" (PDF). Free Radical Biology & Medicine. 81: 158–69. doi:10.1016/j.freeradbiomed.2014.09.014. PMID 25246239.
  81. ^ Béchir, N; Pecchi, E; Vilmen, C; Le Fur, Y; Amthor, H; Bernard, M; Bendahan, D; Giannesini, B (October 2016). "ActRIIB blockade increases force-generating capacity and preserves energy supply in exercising mdx mouse muscle in vivo". FASEB Journal. 30 (10): 3551–3562. doi:10.1096/fj.201600271RR. PMID 27416839.
  82. ^ Tawil, R; McDermott, MP; Pandya, S; King, W; Kissel, J; Mendell, JR; Griggs, RC (January 1997). "A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group". Neurology. 48 (1): 46–9. doi:10.1212/wnl.48.1.46. PMID 9008492.
  83. ^ Kissel, JT; McDermott, MP; Natarajan, R; Mendell, JR; Pandya, S; King, WM; Griggs, RC; Tawil, R (May 1998). "Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group". Neurology. 50 (5): 1402–6. doi:10.1212/wnl.50.5.1402. PMID 9595995.
  84. ^ Kissel, JT; McDermott, MP; Mendell, JR; King, WM; Pandya, S; Griggs, RC; Tawil, R; FSH-DY, Group. (23 October 2001). "Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy". Neurology. 57 (8): 1434–40. doi:10.1212/wnl.57.8.1434. PMID 11673585.
  85. ^ van der Kooi, EL; Vogels, OJ; van Asseldonk, RJ; Lindeman, E; Hendriks, JC; Wohlgemuth, M; van der Maarel, SM; Padberg, GW (24 August 2004). "Strength training and albuterol in facioscapulohumeral muscular dystrophy". Neurology. 63 (4): 702–8. doi:10.1212/01.wnl.0000134660.30793.1f. PMID 15326246.
  86. ^ Elsheikh, BH; Bollman, E; Peruggia, M; King, W; Galloway, G; Kissel, JT (24 April 2007). "Pilot trial of diltiazem in facioscapulohumeral muscular dystrophy". Neurology. 68 (17): 1428–9. doi:10.1212/01.wnl.0000264017.08217.39. PMID 17452589.
  87. ^ Wyeth Initiates Clinical Trial with Investigational Muscular Dystrophy Therapy MYO-029
  88. ^ "Home - ClinicalTrials.gov". ClinicalTrials.gov. Retrieved 2015-09-16.
  89. ^ Malcolm, Emily (18 June 2019). "ACE-083". Muscular Dystrophy News. Retrieved 19 December 2019.
  90. ^ a b c d Landouzy-Dejerine syndrome, whonamedit.com, date accessed March 11, 2007

External links[edit]

External resources